Sun Pharma numbers were slightly below expectations in terms of EBITDA and we do think that though they have guided for a very strong growth through their speciality portfolio, that is a little bit time away.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
